Baculoviral IAP repeat-containing protein 5 (BIRC5) (BIRC5)

Baculoviral IAP repeat-containing protein 5 (BIRC5), commonly known as survivin, is a multifunctional protein that serves as a critical node in both the regulation of mitosis and the inhibition of apoptosis [1, 8]. As the smallest member of the inhibitor of apoptosis (IAP) family, it is uniquely characterized by a single baculovirus IAP repeat (BIR) domain and is expressed in a cell cycle-dependent manner, peaking during the G2/M phase [5, 8]. Survivin is highly overexpressed in nearly all human cancers and fetal tissues but is largely absent in terminally differentiated adult tissues, providing a significant therapeutic window for oncology [1, 3]. Its biological roles include acting as a component of the chromosomal passenger complex (CPC) to ensure proper chromosome segregation and cytokinesis, as well as suppressing programmed cell death by inhibiting caspase activation, often through interactions with XIAP or Smac/DIABLO [5, 10]. In clinical settings, high survivin expression is a well-established biomarker for poor prognosis, tumor recurrence, and resistance to conventional therapies like chemotherapy and radiation [3, 12, 16]. Therapeutic interventions targeting the survivin pathway include small molecule inhibitors of its transcription (e.g., YM155), antisense oligonucleotides (e.g., LY2181308), and immunotherapy approaches such as the SurVaxM vaccine [3, 4, 10, 12].

Other names

SurvivinAPI4EPR-1IAP4SVVApoptosis inhibitor 4

Drugs targeting the survivin pathway employ several distinct mechanisms: (1) transcriptional inhibition of the BIRC5 promoter to reduce mRNA and protein levels (e.g., YM155) [3, 10]; (2) antisense oligonucleotides that trigger the degradation of survivin mRNA (e.g., LY2181308, EZN-3042) [4, 8]; (3) disruption of protein-protein interactions, such as the survivin-HSP90 complex, leading to proteasomal degradation (e.g., Shepherdin) [4, 10]; and (4) immunotherapy/vaccines that prime the immune system to recognize and eliminate survivin-expressing cells (e.g., SurVaxM) [12, 16].